Retrophin Inc (RTRX) Given Average Rating of “Hold” by Analysts

Retrophin Inc (NASDAQ:RTRX) has earned an average rating of “Hold” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $44.00.

RTRX has been the topic of several research analyst reports. BMO Capital Markets restated a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. BidaskClub lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. Finally, ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Monday, November 20th.

Several institutional investors have recently modified their holdings of RTRX. Schwab Charles Investment Management Inc. boosted its position in shares of Retrophin by 35.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 277,688 shares of the biopharmaceutical company’s stock valued at $5,385,000 after acquiring an additional 73,067 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Retrophin by 4.4% during the 2nd quarter. Rhumbline Advisers now owns 47,454 shares of the biopharmaceutical company’s stock valued at $920,000 after acquiring an additional 2,010 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Retrophin during the 2nd quarter valued at about $543,000. SG Americas Securities LLC boosted its position in shares of Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Retrophin by 12.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 434,699 shares of the biopharmaceutical company’s stock valued at $8,429,000 after acquiring an additional 46,967 shares in the last quarter.

Shares of Retrophin (NASDAQ:RTRX) opened at $23.29 on Wednesday. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. The stock has a market cap of $894.00, a price-to-earnings ratio of -17.64 and a beta of 1.45. Retrophin has a 12-month low of $15.55 and a 12-month high of $26.44.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.21). The company had revenue of $40.34 million during the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) earnings per share. sell-side analysts predict that Retrophin will post -1.25 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Retrophin Inc (RTRX) Given Average Rating of “Hold” by Analysts” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2018/01/10/retrophin-inc-rtrx-given-average-rating-of-hold-by-analysts.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

What are top analysts saying about Retrophin? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit